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EDRF modulates renal hemodynamics during unilateral
ureteral obstruction in the rat
ROBERT L. CHEVALIER, BARBARA A. THORNHILL, and R. ARIEL GOMEZ
Department of Pediatrics, The University of Virginia School of Medicine, Charlottesville, Virginia, USA
EDRF modulates renal hemodynamics during unilateral ureteral ob.
struction in the rat. Unilateral ureteral obstruction (UUO) results in
vasoconstriction of the ipsilateral kidney, and vasodilatation of the
intact opposite kidney. To investigate the role of endogenous nitric
oxide, an endothelial-derived relaxing factor (EDRF), in the regulation
of renal hemodynamics during UUO, Sprague-Dawley rats were anes-
thetized for study 24 hours after left UUO or sham-operation. Total
vascular resistance (TVR) and renal vascular resistance (RVR) were
measured using radioactive microspheres during control periods and
following infusion of the nitric oxide synthase inhibitor, L-NAME (2.5
mg/kg). Blood pressure and RVR were increased by L-NAME, with a
greater increment in the RVRJTVR ratio of the kidney with ipsilateral
UUO than in the intact opposite kidney or sham-operated kidneys.
Infusion of L-arginine (L-Arg), a substrate for nitric oxide synthase, did
not alter the RVRJTVR ratio of either kidney of rats with UUO, but
reduced the ratio in sham-operated animals. L-NAME tended to reduce
urine flow and urinary sodium and cyclic GMP excretion, whereas
L-Arg resulted in a marked diuresis, natriuresis, and increased excre-
tion of cyclic GMP in both operative groups. We conclude that EDRF
activity is increased in the kidney with ipsilateral UUO, which serves to
counteract renal vasoconstriction. This response is not limited by
availability of substrate (L.Arg). Vasodilatation of the intact opposite
kidney appears to be mediated by factors other than EDRF.
Although urinary tract obstruction remains a major cause of
renal insufficiency, the pathogenesis of obstructive nephrop-
athy remains incompletely understood. Unilateral ureteral ob-
struction (UUO), a useful model to study the renal response to
urinary tract obstruction, results in decreased renal blood flow
(RBF) to the kidney with ipsilateral UUO and increased blood
flow to the intact opposite kidney [1]. A number of circulating
and paracrine factors have been implicated in this vasoconstric-
tion, including thromboxanes and angiotensin [2, 3]. This in-
creased vasoconstrictor activity appears to be balanced by a
parallel increase in opposing vasodilators, such as prostaglan-
dins [4].
Endothelial-derived relaxing factor is a locally released Va-
soactive compound which modulates vascular resistance [5].
Recently, nitric oxide has been identified as a major EDRF [6],
and appears to contribute significantly to renal vascular tone.
We wished, therefore, to test the hypothesis that vascular
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production of nitric oxide is deficient in the kidney with
ipsilateral UUO, thereby contributing to the increase in renal
vascular resistance. An alternate hypothesis to be considered is
that nitric oxide production is actually enhanced in the kidney
with UUO, in response to augmented activity of vasoconstric-
tors such as angiotensin, thromboxanes, and endothelin.
To distinguish between these two possibilities, experiments
were performed in anesthetized rats subjected to 24-hour UUO.
Systemic and renal vascular resistance were measured using the
radioactive microsphere technique, which allows the determi-
nation of RBF without urine collection. Production of endoge-
nous nitric oxide was inhibited by administration of the potent
and specific inhibitor of nitric oxide synthase, N-nitro-L-argin-
ine-methylester HC1 (L-NAME). Additional animals received
infusion of L-arginine (L-Arg), the substrate for production of
nitric oxide by vascular endothelium. In addition to measure-
ment of hemodynamic variables, urine was collected for deter-
mination of sodium excretion, and of guanosine 3',5'-cyclic
monophosphate (cGMP), which mediates the vasorelaxant ef-
fects of nitric oxide [6].
Methods
Sixty-three male Sprague-Dawley rats weighing 200 to 250 g
(Hilltop Laboratories, Scottdale, Pennsylvania, USA) were
studied. Twenty-four hours prior to experimentation, each
animal was anesthetized with intraperitoneal sodium pentobar-
bital (50 mg/kg) and was subjected to either unilateral ureteral
obstruction (UUO), or to sham operation. In all animals, the left
ureter was exposed through a mid-line abdominal incision. The
ureter was ligated midway between the kidney and bladder with
5-0 silk (UUO groups), or left untouched (sham groups). The
incision was sutured in two layers and the animals were allowed
to recover.
After 22 to 24 hours, the rats were anesthetized with intra-
peritoneal sodium pentobarbital (60 mg/kg), placed on a ther-
mostatically controlled heating table, and a tracheotomy was
performed. A cannula was inserted in ajugular vein for infusion
of saline at 5 ml/kg/hr and the right carotid artery was cannu-
lated to the aortic root and connected to a transducer for
continuous recording of mean arterial pressure. The bladder
was cannulated through a small suprapubic incision. Urine
samples were collected in pre-weighed cups, and were frozen
immediately at —20°C for measurement of cGMP and sodium
concentration. A polyethylene catheter was inserted into the
femoral artery and connected to a constant withdrawal pump
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Table 1. Characteristics of rats
UUO Sham
L-NAME +
Group L-NAME Vehicle L-Arg L-NAME Vehicle L-Arg L-Arg
N 10 10 7 10 10 6 10
Bodyweightg 222±3 210±3 212±5 232±6 216±4 219±7 228±5
Left kidney weight g 1.23 0.04 1.21 0.03 1.24 0.04 0.96 0.02 0.93 0.03 1.13 0.06 1.24 0.06
Right kidney weight g 1.05 0.Ola 1.00 0.04a 1.12 0,04k 1.03 0.02 0.96 0.03 1.17 0.03 1.26 0.06
Left ureteral diameter mm 1.91 0.03 1.85 0.07 1.74 0.12 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0,00
Right ureteral diameter mm 1.00 o.ooa 1.00 o.ooa 1.00 o.ooa 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00
Hematocrit control % 49.2 0.5 48.5 0.5 49.3 0.9 48.2 0.6 49.1 0.9 47.7 1.2 50.0 0.6
Hematocrit treatment % 54.7 0.7k 54.5 l.la 51.4 0.5a 54.6 1.oa 55.1 1.3 51.5 1.3k 53.7 o.8a
TVR control mm Hg/mI/mm 1.56 0.08 2.36 0.19 2.01 0.16 1.70 0.10 2.33 0.23 2.08 0.23 2.02 0.17
TVR treatment mm Hg/mI/mm 4.33 0.33a 3.07 0.29a 3.25 0.3 ia 3.73 0.2l 2.70 0.28 2.95 0.66 3.22 0.23a
a P < 0.05 versus left kidney or versus control
(Harvard Apparatus, South Natick, Massachusetts, USA) for
collection of reference blood flow samples during microsphere
injection. Arterial hematocrit was measured at the beginning of
the experiment and prior to each microsphere injection. All
blood withdrawn was replaced with an equal volume of hep-
arinized donor rat erythrocytes washed with chilled saline and
reconstituted in 4% bovine serum albumin, Fraction V (Sigma,
St. Louis, Missouri, USA) to hematocrit 34 volume percent.
After a 45-minute equilibration period, a 15-minute baseline
urine sample was collected. After 60 minutes, approximately
50,000 latex microspheres 14 1 p.m in diameter, labeled with
85Sr (3M, St. Paul, Minnesota, USA) and suspended in 10%
dextran, were injected into the carotid catheter and flushed with
0.5 ml saline. A reference blood sample was withdrawn simul-
taneously from the femoral arterial catheter at 0.7 mi/mm for 90
seconds.
After a 30 to 45 minute reequilibration period, groups of rats
with UUO or sham-operation received one of three treatments:
a bolus injection of N-nitro-L-arginine-methylester HC1 (L-
NAME) (Bachem, Torrance, California, USA), 10 mg/mi sa-
line, 2.5 mg/kg body weight; saline vehicle, 0.25 mI/kg body
weight; or L-arginine HC1 (Sigma, St. Louis, Missouri, USA),
0.6 g/ml, 300 mg/kg body weight, followed by continuous
infusion at 50 mg/kg/mm. An additional group of sham-operated
rats received a combined bolus of L-Arg and L-NAME (in
doses identical to those receiving the compounds separately),
followed by continuous infusion of L-arginine HC1 at 50 mg/kg!
mm. Fifteen minutes following drug administration, an addi-
tional 15-minute urine collection was obtained. At the end of the
30 minute period a second bolus of 50,000 microspheres,
labeled with '41Ce was injected during withdrawal of a second
reference blood sample. The animals were then sacrificed with
infusion of saturated KC1. The kidneys were removed, decap-
sulated and weighed prior to measurement of radioactivity
(LKW/Wallac 1280 Ultragamma, Gaithersburg, Maryland,
USA).
Urine cGMP concentration was determined by automated
radioimmunoassay as described previously [7]. Urine sodium
was measured by flame photometer (model 435; Corning Glass
Works, Medfield, Massachusetts, USA).
Calculations
Cardiac output, total vascular resistance (TVR), renal blood
flow (RBF) and renal vascular resistance (RVR) were calculated
as described previously [81. To isolate the effects of experimen-
tal manipulations on RVR from remaining vascular beds, the
ratio of RVR to TVR was also determined.
Statistical analysis
For each variable, comparisons were made between
L-NAME, vehicle, and L-Arg treatment groups for control and
treatment periods using analysis of variance (ANOVA) fol-
lowed by Scheffe's post-hoc test. This was done separately for
UUO and sham-operated groups. Comparisons between control
and treatment periods, as well as between left and right kid-
neys, were performed using Student's t-test for paired data.
Results
As shown in Table 1, body weight at the time of study was
greater for sham-operated rats than for animals with left UUO
(ANOVA, P < 0.01). Wet weight of the left kidney and left
ureteral diameter were greater following ipsilateral UUO than
following sham operation (ANOVA, P < 0.001), whereas there
was no difference between groups in weight of the right kidney
or ureteral diameter. There were no differences in hematocrit
between UUO and sham-operated groups either during control
or treatment periods, although there was a significant increase
in hematocrit during the experiment regardless of UUO or
pharmacologic treatment. There was no effect of UUO on TVR
in the control period. In sham-operated rats, TVR increased
following infusion of L-NAME, but not in groups receiving
vehicle or L-Arg. In animals with UUO, however, TVR in-
creased during the experiment in each group.
As shown in Figure 1, there was no difference between
groups in mean arterial blood pressure during the control
period, and infusion of saline vehicle did not alter pressure.
Infusion of L-NAME resulted in a similar increment in blood
pressure regardless of UUO, and L-Arg resulted in a decrease
in pressure in sham-operated animals. Compared to sham-
operated rats (Fig. 2B), renal blood flow was reduced in the left
kidneys of rats with ipsilateral UUO, and blood flow to the
intact right kidneys was greater than that of sham-operated
animals (Fig. 2A, P < 0.001). Infusion of vehicle or L-Arg had
no effect on blood flow to either kidney of UUO or sham-
operated rats, except for a small reduction in left renal blood
flow of animals with UUO receiving saline vehicle infusion.
Infusion of L-NAME resulted in a marked reduction in blood
flow to both kidneys in UUO and sham-operated groups.
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Fig. 1. Mean arterial blood pressure during control () and treatment(l) periods for each of the three treatment groups. A. Rats with 24 h
unilateral (left) ureteral obstruction (UUO); B. Sham-operated rats.
Table I contains the number of animals and their characteristics. *D <
0.05 vs. control period; AP < 0.05 vs. vehicle. Fig. 2. Renal blood flow during control and treatment periods for each
kidney during control and treatment periods. Abbreviations are as for
Figure 1. Symbols are () LK control; () LK treatment; (lJ) RK
control; (l) RK treatment. *p < 0.05 vs. control period; AP < 0.05 vs.
vehicle.
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Compared to sham-operated rats (Fig. 3B), the ratio of RVR
to TVR was greater for left kidneys of rats with ipsilateral UUO
(Fig. 3A), and lower for the intact right kidneys (ANOVA, P <
0.001). Infusion of saline vehicle did not affect the RVRITVR
ratio for rats in either operative group. Infusion of L-NAME,
however, resulted in a selective significant increase in the ratio
of the left kidney of rats with ipsilateral UUO (Fig. 3A). In
contrast, there was no selective effect of L-NAME on vascular
resistance of the renal vascular bed of the intact right kidney of
rats with left UUO (Fig. 3A), or in either kidney of sham-
operated animals (Fig. 3B). Infusion of L-Arg resulted in a
significant reduction in the RVRITVR ratio of both kidneys of
sham-operated rats (Fig. 3B).
Although L-NAME reduced urine flow in sham-operated rats
(Fig. 4B), there was no significant change in animals with UUO
(Fig. 4A). In contrast, infusion of L-Arg resulted in a tenfold
increase in urine flow in rats with either UUO or sham opera-
tion (Fig. 4). Urine sodium excretion followed a similar pattern,
with L-Arg infusion resulting in a significant increase in sodium
excretion regardless of UUO (Fig. 5). Excretion of cGMP was
reduced by infusion of L-NAME in rats with UUO (Fig. 6A)
and in sham-operated animals with saline vehicle infusion (Fig.
6B). Infusion of L-Arg increased cGMP excretion similarly in
both operative groups (Fig. 6).
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Fig. 3. Ratio of renal vascular resistance to total vascular resistance
(RVR/TVR ratio) for each kidney during control and treatment periods.
Abbreviations and symbols are as for Figure 2.
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Fig. 4. A. Urine flow rate for intact right kidney contralateral to left
UUO during control and treatment periods for each of the three
treatment groups. B. Urine flow rate for both kidneys of sham-operated
rats during control and treatment periods. Abbreviations and symbols
are as for Figure 1.
Infusion of L-Arg, on the other hand, reduced mean arterial
blood pressure and selectively reduced RVR in sham-operated
rats. This suggests that synthesis of nitric oxide can be further
stimulated by excess substrate in the normal rat, but not in the
animal with UUO. This could be due to saturation of nitric
oxide synthase or the presence of excess endogenous L-argi-
nine in kidneys of rats with UUO. Blockade of the hypertensive
effect of L-NAME by concurrent infusion of L-Arg indicates
that the inhibitor is specific for nitric oxide synthase. This is
suggested also by its reversal of the effect of L-NAME to
reduce urine flow, sodium excretion, and cGMP excretion.
Compared to other vascular beds, nitric oxide blockade
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Shown in Table 2 is the response to combined L-NAME and
L-Arg infusion in sham-operated rats. Co-administration of
L-Arg blocked the hypertensive response to L-NAME, and
reversed the effects of L-NAME on urine flow, sodium excre-
tion and cGMP excretion (Table 2).
Discussion
In the present study, nitric oxide synthase inhibition with
L-NAME unmasked a marked systemic and renal vasodilatory
effect of endogenous nitric oxide in the anesthetized rat. This is
consistent with previous studies in the anesthetized and con-
scious rat, as well as in the isolated perfused rat kidney [9—13].
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Fig. 5. A. Urinary sodium excretion rate for intact right kidney con-
tralateral to left UUO during control and treatment periods for each of
the three treatment groups. B. Urinary sodium excretion for both
kidneys of sham-operated rats during control and treatment periods.
Abbreviations and symbols are as for Figure 1.
resulted in a greater selective increase in renal vascular resis-
tance of the kidney with ipsilateral UUO. Moreover, the lack of
effect of L-NAME on the RVRJTVR ratio of the kidney
contralateral to UUO, or of kidneys of sham-operated rats,
underscores the localization of increased nitric oxide produc-
tion to the kidney with ipsilateral UUO. These results are
consistent with the hypothesis that nitric oxide production by
the kidney with ipsilateral UUO is increased consequent to
increased local release of vasoconstrictors such as angiotensin
II. Since angiotensin II has been shown to contribute to the
increased RVR and decreased glomerular filtration rate due to
0
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Fig. 6. A. Urinary cGMP excretion for intact right kidney contralateral
to left UUO during control and treatment periods for each of the three
treatment groups. B. Urinary cGMP excretion for both kidneys of
sham-operated rats during control and treatment periods. Abbrevia-
tions and symbols as for Figure 1.
UUO [3], local nitric oxide production may attenuate angioten-
sin-dependent afferent arteriolar vasoconstriction and mesan-
gial cell contraction as demonstrated in vitro [14, 15]. A
negative feedback of EDRF on renin release has also been
demonstrated [16], which may limit ischemic injury resulting
from activation of the intrarenal renin-angiotensin system. Such
a response may be of particular importance, since renal isch-
emia itself has been shown to impair production of EDRF,
which would aggravate the injury [17].
One possibility that must be considered in evaluation of the
renal hemodynamic response to L-NAME is an autoregulatory
adaptation to increased renal perfusion pressure. However, the
normal autoregulatory response to increased blood pressure is a
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Table 2. Effect of combined L-NAME and L-Arg in sham-operated
rats
L-NAME L-Arg
L-NAME +
L-Arg
N 10 6 10
Blood pressure control 133 4 132 4 142 4
mm Hg
Blood pressure 155 2 128 5b 137 5b
treatment mm Hg
Urine flow control 6.42 0.88 5.91 0.71 7.37 1.08
,ul/min
Urine flow treatment 3.2 0.7a 130.9 67a,b 146.5 10.9
pi/min
Urine Na excretion 0.36 0.06 0.43 0.10 0.30 0.09
control p,Eq/,nin
Urine Na excretion 0.14 0.03a 3.50 0.77a,b 493 096a,b
treatment p.Eq/min
Urine cGMP excretion 16.0 2.0 23.0 6.4 29.4 29b
control pmol/min
Urine cGMP excretion 9.0 3.0 61.5 160a,b 25.2 2.6"
treatment pmol/min
a P < 0.05 versus controlb P < 0.05 versus L-NAME
selective increase in RVR, which was proportional to the rise in
TVR both in the intact opposite kidney of rats with UUO as
well as in sham-operated animals (Fig. 3). Previous studies have
demonstrated that acute ipsilateral UUO or ischemic renal
injury actually impair autoregulation of RBF [18, 19]. It is
therefore extremely unlikely that following infusion of
L-NAME, the disproportionate increase in RVRITVR of the
kidney with ipsilateral UUO is due to an exaggerated autoreg-
ulatory response. It is more probable that autoregulation is
attenuated, and that a selective increase in nitric oxide produc-
tion by the obstructed kidney is responsible.
The role of nitric oxide in renal medullary hemodynamics
may have particular relevance for the pathogenesis of obstruc-
tive nephropathy, in which the medulla is most susceptible to
damage. The renal medulla can produce EDRF [20], and
inhibition of nitric oxide formation has been shown to reduce
p02 in the renal medulla and to increase deep medullary
hypoxic injury to thick ascending limbs [21].
While the intrarenal source of increased nitric oxide produc-
tion by the kidney with ipsilateral UUO cannot be determined
from this study, one possibility is inifitration of macrophages,
which is maximal by 24 hours following UUO in the rat [22].
Activated macrophages have been shown to synthesize nitric
oxide derived from L-arginine [231, and may be responsible for
increased nitric oxide production by glomeruli from rats with
experimental nephrotoxic nephritis [24]. Alternatively, cyto-
kines released by infiltrating macrophages could stimulate nitric
oxide production and cGMP formation by glomerular mesangial
cells [25].
The present study demonstrates that concurrent with vaso-
constriction of the kidney with ipsilateral UUO, blood flow to
the intact opposite kidney was increased. Since RVR of the
intact opposite kidney was not selectively increased by infusion
of L-NAME, it would appear that compensatory vasodilatation
of the intact kidney was not due to increased local nitric oxide
synthesis. Moreover, lack of a selective reduction in RVR of
the intact opposite kidney by infusion of L-Arg suggests that
delivery of substrate is not a limiting factor. Recently glomeruli
isolated from kidneys opposite to UUO have been shown to
produce more vasodilatory eicosanoids than glomeruli from
kidneys with ipsilateral UUO [26]. Increased PGE2 and 6-keto-
PGF1 may therefore explain the compensatory vasodilatation
of the intact opposite kidney.
In the present study, infusion of L-NAME reduced diuresis
and natriuresis in sham-operated rats, with qualitatively similar
responses by the intact kidney with contralateral UUO. These
changes were paralleled by reduced urinary excretion of cGMP.
In contrast, infusion of L-Arg resulted in a marked increase in
diuresis, natriuresis, and cGMP excretion in both UUO and
sham-operated rats. These findings are consistent with a role for
EDRF in modulating tubular sodium and water reabsorption,
and cGMP produced by the activation of guanylyl cyclase by
nitric oxide may mediate the response [27—29]. Others have
shown that urinary cGMP is a biological marker of EDRF or
nitric oxide activity [12], and that 8-bromo-cGMP infusion can
prevent the reduction in diuresis and natriuresis in the rat
receiving L-NAME [29]. However, infusion of higher doses of
L-NAME or N-monomethyl-L-arginine (L-NMMA) in con-
scious or anesthetized rats was found to cause an unexpected
diuresis and natriuresis [10, 13]. Although this was ascribed to
pressure natriuresis, the opposite findings in the present study,
in which mean arterial blood pressure increased approximately
20 mm Hg with L-NAME infusion, make such an explanation
unlikely. These discrepancies may be explained by preliminary
studies suggesting that under certain conditions, L-NAME may
directly inhibit tubular Na-K-ATPase [30].
In summary, the present study shows that the vasoconstric-
tion of the kidney following 24-hour ipsilateral UUO is attenu-
ated by enhanced local production of nitric oxide. However,
endogenous nitric oxide activity is not increased in the intact
kidney contralateral to UUO, despite a compensatory increase
in RBF. Lack of a selective L-Arg-dependent decrease in RVR
of the kidney with ipsilateral UUO argues against a deficit in
local nitric oxide production, or in availability of substrate.
These findings are in contrast to a recent report in which it was
concluded that L-Arg production is decreased following unilat-
eral release of bilateral ureteral obstruction [31]. This is perhaps
not surprising, in view of the significant differences in the renal
response to bilateral compared to unilateral ureteral obstruction
[1]. Additional studies will be required to elucidate the regula-
tory interactions of EDRF in the response to ureteral obstruc-
tion.
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